effect of dulexetine on paclitaxel- induced peripheral Neuropathy

Phase 3

Recruiting

• Conditions: Paclitaxel induced peripheral neuropathy.; Polyneuropathy (diseases of several nerves) and other disorders of the peripheral nervous system; G60-G64

• Registration Number: IRCT20201115049390N1
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

1- Women with breast cancer (according to the pathological tests and graphies)
Treat with paclitaxel 80 mg once a week
checked with Beck Depression Inventory (BDI-II) .
not treated any other chemotherapy drugs
with Life expectancy over than 6 months

Exclusion Criteria

Pregnant or breastfeeding women
Women with a history of diabetes or peripheral vascular disease
Woman with a history of liver and kidney disease
Woman with a history of Psychiatric diseases such as bipolar disorder
woman a history of peripheral nerve disease such as carpal tunnel

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reducing peripheral neuropathy pain. Timepoint: Evaluation of neuropathic pain at the beginning and end of the intervention with measurement of TNF at the beginning and end of the intervention in two parallel groups. Method of measurement: Using( The Brief Pain Inventory); ( National Cancer Institute-Common Toxicity Criteria); von Frey or monofilament test; Visual analog scale; TNF alpha ELISA Kits.